Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report

Author(s): Aliki I. Venetsanopoulou, Konstantina Mavridou, Eleftherios Pelechas, Paraskevi V. Voulgari and Alexandros A. Drosos*

Volume 20, Issue 4, 2024

Published on: 12 January, 2024

Page: [451 - 454] Pages: 4

DOI: 10.2174/0115733971266803231117072453

Price: $65

Abstract

Background: Tumor necrosis factor alpha (TNFα) is a pivotal cytokine involved in the pathogenesis of certain inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthropathies, and inflammatory bowel diseases. In the last two decades, TNFα inhibitors (TNFi) have revolutionized the treatment and outcome of the above disorders. However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may present as the same type of clinical indications for which the TNFi effectively used. Thus, they may display as arthritis, uveitis, colitis, psoriasis, and several other cutaneous clinical manifestations, among them the development of morphea, a localized scleroderma skin lesion.

Case Presentation: We describe a 58-year-old woman with seronegative RA, refractory to methotrexate, who was treated with ABP-501 (Hefiya), an adalimumab (ADA) biosimilar and developed an oval-shaped, deep skin lesion of approximately 3.5cm in size, affecting the left part of her back compatible with morphea 3 months after the initiation of therapy. ADA biosimilar was discontinued and two months later, she had substantial skin improvement.

Conclusion: This is the first report of morphea manifestation during TNFi biosimilar since the patient had no other trigger factors for morphea development like trauma and infections. Physicians dealing with patients treated with TNFi biosimilars should be aware of paradoxical skin reactions, among them morphea; thus, close monitoring, a minute and careful clinical examination, and a follow- up check are required.

« Previous Next »
Graphical Abstract

[1]
Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ. Morphea and eosinophilic fasciitis: An update. Am J Clin Dermatol 2017; 18(4): 491-512.
[http://dx.doi.org/10.1007/s40257-017-0269-x] [PMID: 28303481]
[2]
Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345(5): 340-50.
[http://dx.doi.org/10.1056/NEJM200108023450506] [PMID: 11484692]
[3]
Sfikakis PP, Bournia VK, Sidiropoulos P, et al. Biologic treatment for rheumatic disease: Real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 2017; 35(4): 579-85.
[PMID: 28281458]
[4]
Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: Where we stand today in rheumatoid arthritis. Expert Rev Clin Immunol 2022; 18(5): 485-93.
[http://dx.doi.org/10.1080/1744666X.2022.2064275] [PMID: 35535405]
[5]
Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum 2005; 52(8): 2513-8.
[http://dx.doi.org/10.1002/art.21233] [PMID: 16052599]
[6]
Drosos AA, Pelechas E, Kaltsonoudis E, Markatseli TE, Voulgari PV. Biologic therapies and autoimmune phenomena. Mediterr J Rheumatol 2021; 32(2): 96-103.
[http://dx.doi.org/10.31138/mjr.32.2.96] [PMID: 34447904]
[7]
Skalkou A, Pelechas E, Voulgari PV, Drosos AA. TNF-induced Lupus. A case-based review. Curr Rheumatol Rev 2022; 18(1): 72-82.
[http://dx.doi.org/10.2174/1573397117666211102094330] [PMID: 34727862]
[8]
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67(4): 567-70.
[http://dx.doi.org/10.1136/ard.2007.075663] [PMID: 17728330]
[9]
Hernández MV, Ruiz-Esquide V, Gómez-Caballero ME, Gómez-Puerta JA, Cañete JD, Sanmartí R. Relapsing polychondritis: A new adverse event secondary to the use of tumour necrosis factor antagonists? Rheumatology 2011; 50(8): 1523-5.
[http://dx.doi.org/10.1093/rheumatology/ker144] [PMID: 21593064]
[10]
Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009; 38(5): 328-31.
[http://dx.doi.org/10.1080/03009740902922612] [PMID: 19579151]
[11]
Maliyar K, Mufti A, Sachdeva M, Lytvyn Y, Salsberg J, Yeung J. Development of morphea in patients receiving biologic therapies: A systematic review. J Am Acad Dermatol 2021; 84(4): 1081-5.
[http://dx.doi.org/10.1016/j.jaad.2020.06.1027] [PMID: 32687966]
[12]
Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2018; 18(3): 317-22.
[http://dx.doi.org/10.1080/14712598.2018.1430760] [PMID: 29350566]
[13]
Mattozzi C, Richetta AG, Cantisani C, et al. Morphea, an unusual side effect of anti-TNF-alpha treatment. Eur J Dermatol 2010; 20(3): 400-1.
[http://dx.doi.org/10.1684/ejd.2010.0946] [PMID: 20299314]
[14]
Ramírez J, Hernández MV, Galve J, Cañete JD, Sanmartí R. Morphea associated with the use of adalimumab: A case report and review of the literature. Mod Rheumatol 2012; 22(4): 602-4.
[http://dx.doi.org/10.3109/s10165-011-0550-4] [PMID: 22095405]
[15]
Stewart FA, Gavino AC, Elewski BE. New side effect of TNF-alpha inhibitors: Morphea. Skinmed 2013; 11(1): 59-60.
[PMID: 23540081]
[16]
Chimenti MS, Teoli M, Stefani AD, Giunta A, Esposito M, Perricone R. Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. Eur J Dermatol 2013; 23(2): 273-4.
[http://dx.doi.org/10.1684/ejd.2013.1929] [PMID: 23557629]
[17]
Inoue-Nishimoto T, Hanafusa T, Igawa K, et al. Possible association of anti-tumor necrosis factor-α antibody therapy with the development of scleroderma-like changes with lichen planus. Eur J Dermatol 2015; 25(5): 513-5.
[http://dx.doi.org/10.1684/ejd.2015.2631] [PMID: 26242643]
[18]
Torrente-Segarra V, Campo P, Heredia S, Heras-Mulero C, Bonet M. Linear localized morphea associated with golimumab in a patient with spondyloarthritis. Rheumatol Clin 2020; 16(4): 303-5.
[http://dx.doi.org/10.1016/j.reumae.2018.06.001]
[19]
Magaña O, Taberner J, Góngora MM, Contreras A. Morphea in a patient with psoriasis on treatment with ustekinumab: Comorbidity or adverse effect? Actas Dermo-Sifiliográficas 2017; 108(5): 487-9.
[http://dx.doi.org/10.1016/j.adengl.2017.03.021] [PMID: 28110825]
[20]
Steuer AB, Peterson E, Lo Sicco K, Franks AG Jr. Morphea in a patient undergoing treatment with ustekinumab. JAAD Case Rep 2019; 5(7): 590-2.
[http://dx.doi.org/10.1016/j.jdcr.2019.05.008] [PMID: 31312709]
[21]
Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med 2021; 385(7): 628-39.
[http://dx.doi.org/10.1056/NEJMra1909094] [PMID: 34379924]
[22]
Diab M, Coloe JR, Magro C, Bechtel MA. Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 2010; 146(6): 601-4.
[http://dx.doi.org/10.1001/archdermatol.2010.120] [PMID: 20566921]
[23]
Ferguson ID, Weiser P, Torok KS. A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. Open Rheumatol J 2015; 9(1): 30-5.
[http://dx.doi.org/10.2174/18743129014090100030] [PMID: 26161155]
[24]
Distler JHW, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor α in fibrotic diseases. Arthritis Rheum 2008; 58(8): 2228-35.
[http://dx.doi.org/10.1002/art.23645] [PMID: 18668576]
[25]
Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk. Semin Arthritis Rheum 2010; 40(2): 147-63.
[http://dx.doi.org/10.1016/j.semarthrit.2009.09.001] [PMID: 19914686]
[26]
Lafyatis R. Transforming growth factor β—at the centre of systemic sclerosis. Nat Rev Rheumatol 2014; 10(12): 706-19.
[http://dx.doi.org/10.1038/nrrheum.2014.137] [PMID: 25136781]
[27]
Redente EF, Keith RC, Janssen W, et al. Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am J Respir Cell Mol Biol 2014; 50(4): 825-37.
[http://dx.doi.org/10.1165/rcmb.2013-0386OC] [PMID: 24325577]
[28]
Torok KS, Kurzinski K, Kelsey C, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum 2015; 45(3): 284-93.
[http://dx.doi.org/10.1016/j.semarthrit.2015.06.006] [PMID: 26254121]
[29]
Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003; 207(2): 141-7.
[http://dx.doi.org/10.1159/000071783] [PMID: 12920362]
[30]
Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. Cutaneous autoimmune phenomena of the anti-TNFa biosimilars. casebased review. Curr Rheumatol Rev 2021; 17(2): 267-70.
[http://dx.doi.org/10.2174/1573397116666201119151349] [PMID: 33213352]
[31]
Pelechas E, Voulgari PV, Drosos AA. TNFα inhibitor biosimilars associated with alopecia areata. Case-based review. Rheumatol Int 2022; 42(6): 1113-7.
[http://dx.doi.org/10.1007/s00296-022-05129-w] [PMID: 35429289]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy